Market Overview
| Study Period | 2020 - 2031 |
|---|---|
| Market Size (2026) | USD 34.26 Billion |
| Market Size (2031) | USD 48.3 Billion |
| Growth Rate (2026 - 2031) | 7.11% CAGR |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players *Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. | |
Artificial Organs And Bionics Market Analysis by Mordor Intelligence
Artificial organs and bionics market size in 2026 is estimated at USD 34.26 billion, growing from 2025 value of USD 31.99 billion with 2031 projections showing USD 48.3 billion, growing at 7.11% CAGR over 2026-2031. Size expansion is being shaped by converging breakthroughs in biomaterials, miniaturized electronics, and 3-D bioprinting, all of which compress development timelines and lift clinical adoption of cardiovascular, renal, and neuro-prosthetic devices. Stretched transplant waiting lists and fast-track regulatory programs are spurring investment in total artificial hearts, wearable artificial kidneys, and next-generation brain–computer interfaces. Defense-funded limb-restoration programs have unlocked neural-interface know-how that is flowing into civilian solutions, while insurers’ gradual acceptance of home-based bionic therapies broadens the treated population. Supply-chain fragilities surrounding rare-earth sensors and high-end chips remain a watchpoint, yet growing regional manufacturing footprints in Asia-Pacific are easing part of that exposure.
Key Report Takeaways
- By device type, artificial organs led with 69.58% revenue share in 2025; bionics is projected to expand at an 8.05% CAGR to 2031.
- By technology, wearable and extracorporeal systems held 54.71% of the artificial organs and bionics market share in 2025, while implantable systems are slated for the highest CAGR at 9.10% through 2031.
- By end user, hospitals and surgical centers accounted for 47.10% of the artificial organs and bionics market size in 2025, whereas home-care and ambulatory settings are growing at 9.05% CAGR during 2026-2031.
- By geography, North America retained 38.25% share of the artificial organs and bionics market in 2025, while Asia-Pacific is forecast to register the fastest regional CAGR at 10.30% to 2031.
Note: Market size and forecast figures in this report are generated using Mordor Intelligence’s proprietary estimation framework, updated with the latest available data and insights as of 2026.
Global Artificial Organs And Bionics Market Trends and Insights
Drivers Impact Analysis*
| Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Rapid biomaterial, micro-electronics & 3-D bio-printing advances | +2.1% | North America, Europe, core APAC | Medium term (2-4 years) |
| Rising incidence of chronic organ failure & disabilities | +1.8% | Global, concentrated in North America & Europe | Long term (≥ 4 years) |
| Scarcity of donor organs | +1.5% | Global, acute in developed markets | Medium term (2-4 years) |
| Fast-track regulatory pathways | +1.2% | North America & EU, expanding to APAC | Short term (≤ 2 years) |
| Defence-funded limb-restoration programmes | +0.9% | North America and allied nations | Short term (≤ 2 years) |
| Source: Mordor Intelligence | |||
Rising Incidence of Chronic Organ Failure & Disabilities
Degenerative ailments are swelling the addressable pool for cardiac assist devices, renal replacements, and neuro-prosthetics. Cardiovascular disease affects 49 million people in the EU, energising demand for mechanical circulatory support systems. Japan’s insulin-producing iPS-cell trials underscore momentum behind a bioartificial pancreas for 139,000 local type 1 diabetes patients. Ageing populations translate into rising stroke-related motor deficits, setting the stage for brain–computer interfaces that restore communication and mobility. The U.S. Department of Veterans Affairs is backing 25 prosthetics-oriented projects in FY 2025, signalling continuing long-term demand.
Scarcity of Donor Organs
More than 103,000 Americans wait for transplants; in Japan, fewer than 3% of organ-failure patients receive brain-dead donations, reinforcing demand for alternatives. FDA-sanctioned pig-organ trials in 2025 are emblematic of the shift toward xenotransplantation. Bridge-to-transplant devices such as the Carmat Aeson artificial heart have kept 30 European patients alive for an average of 156 days. China’s 45-gram pediatric artificial heart answers an acute need in children’s cardiac support.
Rapid Biomaterial, Micro-Electronics & 3-D Bio-Printing Advances
Stanford teams have grown vascularised heart and liver organoids, a step toward size-appropriate constructs for human use[1]Patrick Monahan, “Stanford Scientists Grow Vascularized Heart and Liver Organoids,” med.stanford.edu. 3-D-bioprinted livers transplanted into mice achieved 90% survival, validating the concept of printed human grafts. Brain–computer interface studies restored real-time speech in ALS patients. Hydrogel surface chemistries are damping inflammatory reactions, lengthening implant lifespans. Soft-robotic hearts model natural contraction patterns, trimming thrombosis risk.
Defence-Funded Limb-Restoration Programmes (Post-2024)
The U.S. Department of Defense earmarked USD 141 billion for RDT&E in FY 2025, funnelling capital into neural interfaces and high-durability prosthetics. DARPA runs four active bionics initiatives targeting electrode arrays and cybernetic limbs. The Defence Health Agency catalogued 120 medical AI use-cases, many focused on remote monitoring for advanced prostheses. Military performance specifications are fast-tracking ruggedised, lightweight materials that later enter civilian supply chains.
Restraints Impact Analysis*
| Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| High procedure & device cost | -1.4% | Global, acute in emerging markets | Medium term (2-4 years) |
| Biocompatibility issues & device malfunctions | -0.8% | Global, regulatory spotlight in North America & EU | Short term (≤ 2 years) |
| Supply-chain fragility of rare-earth sensors & chips | -0.6% | Global, concentrated impact in APAC manufacturing | Short term (≤ 2 years) |
| Source: Mordor Intelligence | |||
High Procedure & Device Cost
Robotic knees can reach USD 51,000, and private insurers often cap prosthetic reimbursement, leaving patients exposed to six-figure out-of-pocket bills. Colorado’s Medicare-parity law illustrates patchy progress on coverage mandates. Total artificial heart therapy, including surgery and follow-up, can surpass USD 500,000 per person, restricting uptake to high-resource centers. The cost barrier is sharper in emerging markets, where reimbursement rates lag device prices.
Biocompatibility Issues & Device Malfunctions
Thrombotic complications continue to challenge mechanical circulatory devices despite anticoagulation regimens. A pig-kidney xenograft failed after four months, highlighting lingering immunological hurdles. FDA warnings on systemic reactions to certain metal implants have compelled redesigns of joint and cardiovascular devices. Scar tissue around electrode arrays degrades signal fidelity, prompting ultra-soft polymer research.
*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.
Segment Analysis
By Device Type: Artificial Organs Lead Despite Bionic Acceleration
Artificial organs commanded 69.58% of the artificial organs and bionics market in 2025 as transplant shortages sustained demand for ventricular assist devices and emerging bioartificial kidneys. Bionics is tracking an 8.05% CAGR to 2031, aided by miniaturised brain-computer interfaces that now facilitate speech and fine-motor control. The artificial organs and bionics market size for heart devices alone is projected to expand at 7.52% CAGR, supported by FDA breakthrough tags for titanium total artificial hearts.
Clinical momentum is evident in renal assist systems where Roivios obtained breakthrough designation and is preparing U.S. pivotal trials. Bio-printed liver constructs and gene-edited pig livers are progressing through early-phase studies, signalling pipeline depth. Neuro-bionics growth is amplified by AI-driven control algorithms that adapt in milliseconds to user intent. Collectively, these innovations anchor long-term revenue visibility across the artificial organs and bionics market.
By Technology: Implantable Systems Gain Ground Through Innovation
Wearable and extracorporeal platforms held 54.71% share in 2025, yet implantables are climbing faster at 9.10% CAGR as biocompatible polymers, rechargeable batteries, and thin-film electronics enable long-term in-body operation. Cochlear-implant pioneers have demonstrated totally implantable devices that obviate external microphones, strengthening the artificial organs and bionics market proposition for discreet therapies.
Leadless pacemakers such as Abbott’s AVEIR DR have shown 98.3% implantation success, reinforcing physician confidence. Externally, AI-enhanced hearing aids can now distinguish speech from 50 dB of background noise, extending wearable device relevance. Integration of wireless charging with fully implanted LVADs removes percutaneous cables, reducing infection risk and improving quality of life. Such cross-pollination of ideas keeps investment flowing into the artificial organs and bionics market.
By End User: Home-Care Transformation Drives Growth
Hospitals held 47.10% share in 2025, yet home-care and ambulatory settings are projected to expand at 9.05% CAGR as device makers embed Bluetooth Low-Energy chips, cloud analytics, and AI-driven alerts. The artificial organs and bionics market size for outpatient channels is expected to surpass USD 10.73 billion by 2031, underpinned by reimbursement reforms that now cover remote programming of cochlear implants and pacemakers.
The Department of Veterans Affairs is piloting portable exoskeletons that users calibrate via smartphone, demonstrating how remote monitoring shortens inpatient rehab. Private clinics such as Open Bionics service centers support custom socket fitting and firmware updates, reinforcing a distributed care model. Advances in wireless power transfer and cloud-based dashboards are therefore re-shaping utilisation patterns across the artificial organs and bionics market.
Geography Analysis
North America retained 38.25% share of the artificial organs and bionics market in 2025 on the back of an established FDA fast-track framework and robust venture funding. Investors topped USD 2 billion in disclosed U.S. deals during 2024, half of which went to cardiac and neuro-prosthesis start-ups. The region’s mature reimbursement infrastructure continues to favour early adoption, yet price sensitivity is rising as payers scrutinise cost-effectiveness.
Asia-Pacific is the fastest-growing region with a 10.30% CAGR, catalysed by Japan’s universal artificial blood that maintains two-year shelf life across all blood types. China’s triple-integrated brain-spine interface enabled paraplegic patients to regain over-ground walking within weeks, positioning domestic players at the cutting edge of neuro-prosthetics. Pediatric device innovation is also notable: a 45-gram artificial heart designed for small children filled a vital niche, reinforcing regional clinical leadership.
Europe sustains a technology leadership role through companies such as Carmat, whose Aeson artificial heart received CE marking as a bridge-to-transplant therapy. German transplant centres reported the first fully implantable artificial-heart discharge to home care, broadening real-world validation. Parallel initiatives in organ-preservation perfusion systems further tighten the supply-demand gap for donor organs, keeping Europe firmly inside the high-innovation quadrant of the artificial organs and bionics market.
Regulatory Landscape
In the United States, artificial organs and bionics products are regulated as medical devices under the FDA framework, with additional attention on software functions in life-sustaining implants and connected wearables. FDA actions relevant to this market include updates to cardiovascular device regulations under 21 CFR Part 870 (effective April 30, 2026) and ongoing alignment of submissions to recognized consensus standards such as the FDA-recognized ISO 10993-1:2025 for biological evaluation of medical devices used in cardiovascular implants and artificial organ applications.
In Europe, the Medical Device Regulation (EU) 2017/745 continues to govern Class III and implantable devices central to this market, supported by Medical Device Coordination Group (MDCG) guidance to harmonize interpretation and evidence expectations across member states. Commission Delegated Regulation (EU) 2026/1451 (published March 20, 2026) amended MDR provisions by updating the list of implantable and Class III devices exempted from prior clinical investigation requirements, shaping how select high-risk devices plan clinical evidence pathways. On standards, ISO workstreams influencing device design controls and verification include ISO/DIS 7198 (cardiovascular implants and extracorporeal systems) progressing in 2026 and ISO/AWI 26302 being developed for ventricular assist devices and total artificial hearts.
Competitive Landscape
The artificial organs and bionics market is moderately fragmented: the top five firms hold a significant revenue, leaving room for nimble specialists. Johnson & Johnson’s USD 16.6 billion take-over of Abiomed underscores the strategic value of proven cardiac platforms. BD’s USD 4.2 billion acquisition of Edwards’ Critical Care unit and Teleflex’s EUR 760 million (USD 878.2 million) purchase of BIOTRONIK’s vascular assets illustrate ongoing portfolio concentration.
Challenger brands are scaling quickly. BiVACOR secured USD 13 million to advance its lightweight titanium artificial heart that delivers pulsatile flow using a magnetically levitated rotor. Synchron’s endovascular brain-computer interface circumvents open-brain surgery, earning FDA investigational-device exemption and fostering differentiation on safety. eGenesis is moving 10-gene-edited pig organs into first-in-human trials after promising non-human primate data, widening competitive parameters.
Incumbents maintain an edge in scale manufacturing and regulatory know-how, yet smaller innovators exploit agility to capture niches such as pediatric hearts and fully implantable cochlear systems. AI-powered hearing aids, augmented-AI exoskeletons, and next-generation wireless LVADs exemplify how software capabilities now shape hardware leadership across the artificial organs and bionics market.
Artificial Organs And Bionics Industry Leaders
Abiomed Inc
Boston Scientific Corporation
Ossur
Baxter International
Medtronic plc
- *Disclaimer: Major Players sorted in no particular order
Market Opportunities and Future Outlook
Near-term opportunity in the artificial organs and bionics market centers on technologies that lower procedural burden while widening addressable use settings, especially implantables with improved safety profiles and hardware-software designs built for service. FDA activity such as the December 2025 PMA supplement (P030011/S096) for SynCardia Systems Freedom Driver design and component modifications reflects continued commercial pathway maintenance for total artificial heart ecosystems. It also creates room for suppliers focused on durability, portability, and service logistics that support bridge-to-transplant workflows.
Another opportunity area is the engineering shift toward microfluidic and additive-manufactured organ-replacement platforms that can be manufactured and iterated faster than monolithic systems, with early-stage proof points emerging in 2026. Published work on microfluidic artificial lung prototypes using hybrid additive manufacturing (June 2026, National University of Singapore/University of Toronto researchers) and MIT research on methods to grow artificial blood vessels (July 2026) points to active efforts to improve oxygen transfer efficiency, blood compatibility, and vascular integration, which remain bottlenecks for next-generation artificial organs. In bionics, higher-DOF soft neuroprosthetic hands demonstrated in 2026 research supports progress in dexterity restoration and broadens clinical value propositions beyond basic grasp, aligning with home-care and ambulatory monitoring models already gaining traction in the market.
Recent Industry Developments
- June 2026: Medtronic completed the acquisition of Scientia Vascular for USD 550 million, adding neurovascular guidewires and catheter capabilities to its access and therapeutic portfolio. The acquisition extends procedural tool coverage in neurovascular care, an adjacency for neural bionics and neuro-interventional workflows that intersect with implantable neuromodulation and monitoring ecosystems.
- May 2026: Boston Scientific announced a USD 1.5 billion investment for a 34% equity stake in MiRus LLC, along with an exclusive option to acquire the SIEGEL balloon-expandable transcatheter aortic valve replacement system for an additional USD 3 billion. The deal increases competitive pressure in structural heart interventions and can affect adjacent adoption dynamics for mechanical circulatory support and other cardiac implant categories through consolidated hospital relationships and platform-based selling.
- May 2025: OrganOx raised funding from Intuitive Ventures and Terumo Ventures to expand its normothermic liver perfusion platform, which has been used in more than 5,000 transplant procedures. Scaling organ-preservation infrastructure supports higher transplant throughput and reinforces clinical demand for complementary bridge technologies and peri-operative systems used alongside artificial organ therapies.
Research Methodology Framework and Report Scope
Market Definition and Coverage
This market covers revenues generated from artificial organs and bionic systems that replace or support a lost body function, including implantable and external devices used for long term therapy or rehabilitation, across all major regions.
Scope exclusions: We do not count xenotransplant approaches, purely biologic tissue grafts, or basic orthopedic implants that do not provide organ or bionic function.
Segmentation Overview
- By Device Type
- Artificial Organs
- Artificial Heart
- Artificial Kidney
- Artificial Lungs
- Artificial Liver
- Artificial Pancreas
- Others
- Bionics
- Vision Bionics
- Ear Bionics
- Orthopedic Bionics
- Cardiac Bionics
- Neural Bionics
- Artificial Organs
- By Technology
- Implantable Devices
- Wearable / Extracorporeal Devices
- By End User
- Hospitals & Surgical Centres
- Specialty & Rehabilitation Clinics
- Home-care & Ambulatory Settings
- Military & Veterans Care Systems
- Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Data Sources, Market Sizing, and Validation
Desk Research
Desk work started by mapping demand signals around organ failure, disability burden, and procedure volumes, because these are the real world anchors that later constrain any revenue model. Public sources such as the World Health Organization, the US CDC, the World Bank, and OECD health statistics helped frame patient pools and care access patterns by region.
We also used regulatory and safety disclosures such as FDA device databases and selected EU MDR public records to understand device categories, approval timing, and replacement cycles. Trade association publications, peer reviewed clinical journals, and company filings and investor presentations were used to cross check adoption trends and pricing direction. Where available, a paid subscription for company financials and another for patents were referenced to standardize revenue splits and confirm innovation intensity, then assumptions were adjusted back to what can be defended with public evidence. These sources are illustrative only, and we also reviewed other public materials for data collection, validation, and clarification.
Primary Interviews and Surveys
Primary interviews and surveys were used to confirm how devices are purchased, how reimbursement and tendering shape realized prices, and how quickly newer bionic features are being adopted in different care settings. We spoke with manufacturers, distributors, clinicians, biomedical engineers, and procurement roles across the Americas, EMEA, and APAC so desk assumptions could be pressure tested, and any gaps in volumes, replacement cycles, and pricing could be closed with practical inputs.
Distribution of primary research fieldwork respondents
| Company type | Respondent position | Region |
|---|---|---|
| Top tier: 32% | CXOs: 12% | APAC: 43% |
| Mid tier: 52% | Functional/Unit leaders: 42% | EMEA: 36% |
| Smaller Players: 16% | Managers: 46% | Americas: 21% |
Market-Sizing & Forecasting
The core sizing logic is built from the top down by reconstructing the treated demand pool using disease burden, procedure rates, device eligibility, and care access, and then translating that demand into revenues using region specific price ranges and replacement timing. After shaping the demand pool, we cross checked it with selective bottom up approximations such as sampled ASP x unit volumes for priority device groups, along with distributor channel checks to keep totals realistic.
Inputs that mattered most included transplant waiting list pressure and organ failure incidence, implant and procedure volumes by therapy type, average selling price bands by region, device lifetime and replacement cadence, reimbursement coverage direction, and the pace of approvals for new device generations. Where direct volumes were not visible in public reporting, we handled gaps using proxy indicators like hospital procedure intensity, installed base estimates, and clinician feedback on utilization rates.
For forecasting, scenario analysis was used with a central case anchored to expected procedure growth and reimbursement stability, then adjusted using expert views on adoption speed for next generation bionics and key supply constraints. Growth paths were checked for plausibility by ensuring implied unit growth did not outrun the underlying patient pool and that price progression stayed consistent with tendering and payer dynamics.
Data Validation & Update Cycle
Validation was done through multiple checks that compare the model outputs against independent signals, and then flag outliers for review before sign off. Pricing and volume assumptions were reviewed across regions, and unusual jumps were traced back to a specific cause such as a regulation change, a reimbursement update, or a step change in procedure capacity.
When a mismatch persisted, the relevant assumptions were revisited and, if needed, expert contacts were re engaged to confirm what changed in purchasing, availability, or clinical practice. Reports are refreshed annually, and interim updates are completed when there are material events that can shift adoption or pricing. Before delivery, a final pass is made so the numbers reflect the latest available public updates and validated field feedback.
Mordor Intelligence's Global Artificial Organs Bionics Market Market Size Versus Other Published Estimates
Published market sizes for artificial organs and bionics can differ even when the topic sounds the same, because the boundaries around what gets counted are not always consistent. Differences usually come from what product families are included, which year is treated as the starting point, how prices are normalized across currencies, and whether the demand pool is tied to procedure and patient signals.
Procedure volume checks, regulatory category mapping, and cross region price band validation are the evidence points that keep Mordor Intelligence's estimate aligned to devices that truly replace organ or sensory function, rather than broader implant buckets. Other estimates may also diverge because they use manufacturer revenue recognition logic, include adjacent categories like general implants, or apply a more aggressive adoption curve for newer bionics without re checking replacement cycles and payer coverage.
Benchmark comparison
| Source | Market Size | Gaps in Research Methodology |
|---|---|---|
| Mordor Intelligence | USD 34.26 B (2026) | |
| Global Consultancy A | USD 35.86 B (2025) | Uses manufacturer side revenue framing with a different base year and can reflect factory gate values that bundle related services, which shifts totals versus a demand anchored treated pool approach. |
| Regional Consultancy B | USD 23.50 B (2024) | Starts earlier with a smaller starting pool and typically applies tighter inclusion of device categories and conservative adoption assumptions, which can understate later year totals if procedure growth and pricing bands are updated unevenly. |
The spread in the table is mainly explained by scope boundaries, year selection, and how pricing and adoption are carried forward. By keeping the count tied to therapy relevant devices, checking implied units against procedure capacity, and normalizing prices by region, the final number stays traceable and repeatable for planning.
Key Questions Answered in the Report
What is the projected value of the artificial organs and bionics market by 2031?
The market is expected to reach USD 48.3 billion in 2031 on a 7.11% CAGR trajectory.
Which segment currently dominates the artificial organs and bionics market?
Artificial organs lead with 69.58% device-type share, driven by critical demand in cardiac and renal support.
Why is Asia-Pacific the fastest-growing regional market?
Breakthroughs such as Japan’s universal artificial blood and China’s brain-spine interfaces, combined with rising healthcare investment, propel a 10.30% CAGR through 2031.
How are implantable systems gaining traction over wearable devices?
Advances in biocompatible materials, wireless charging, and miniaturised electronics enable fully internalised solutions that are growing at 9.10% CAGR.
What are the main challenges limiting broader adoption?
High procedure costs, biocompatibility hurdles, and supply-chain dependence on rare-earth sensors continue to temper growth despite strong technology momentum.
Which recent regulatory milestone could reshape the competitive landscape?
The FDA’s approval of first-in-human trials for gene-edited pig organs signals a potential long-range solution to organ scarcity and a new competitive frontier.
Page last updated on:
